THE EVALUATION ATTEMPTS IN ANTI-VEGF THERAPY OF AMD MACULAR EDEMA

• Main Authors: A. V. Tereshchenko, Y. A. Belyi, M. A. Kovalevskaya, S. O. Milyutkina
• Format: Article
• Language: Russian
• Published: Publishing house "Ophthalmology" 2015-10-01
• Series: Офтальмохирургия
• Subjects: age-related macular degeneration; macular edema; 3d-computer threshold amsler grid test (3d-ctag); ranibizumab
• Online Access: https://www.ophthalmosurgery.ru/jour/article/view/64

Purpose. Improving the efficiency of diagnosis and treatment of the wet AMD by dynamic evaluation of macular function. Мaterial and methods. The study included 52 patients (65 eyes) with the wet AMD which underwent intravitreal injection of Ranibizumab. Duration of complaints: group 1 (n=20) – less than 4 months, group 2 (n=24) – 4-12 months, group 3 (n=22): more than 12 months. Additionally the 3D-CTAG was performed in all patients. Criteria: a relation of the visual field loss volume to the vision top (VLRH). Results. In treatment 1 month after Ranibizumab the Group 1: VLRH increased from 2.78±0.18 to 1.26±0.12 insmall CNV, from 11.19±0.69 to 5.11±0.74 inmiddle CNV, 35.33±3.10 to 17.34±1.07% in % of 693000 [deg2%] in big CNV (p<0,01). Group 2: VLRH = 1.29±1.68 to 1.14±0.65 insmall CNV; 12.92±1.99 to 8.92±0.28 inmiddle CNV, 23.79±13.36 to 13.65±3.65 in% of 693000 [deg2%] in big CNV (p<0,01). Group 3: VLRH = 12.79±1.2 to 20.16±8.32 inmiddle CNV, 27.58±2.48 to 41.53±13.48% in % of 693000 [deg2%] in big CNV.Conclusions. Early anti-VEGF therapy reduces scotomas in wet AMD patients but in a long-term inactive CNV it increases the risk of visual function reduction.